STA Pharmaceutical, a subsidiary of WuXi AppTec, has signed an investment agreement with the government of Shanghai, Jinshan District, China to build a new research & development (R&D) center.

The new facility will support WuXi STA’s global pharmaceutical development and manufacturing platform. The new R&D center will be located next to the company’s existing Jinshan drug-substance manufacturing site and will add more than 30,000 square meters of laboratory space and 500 scientists. Upon completion, the expanded Jinshan campus will be able to offer an integrated one-site service for active pharmaceutical ingredients (APIs) and advanced intermediates from preclinical and clinical development through to global commercial launch. The new campus will also provide access to technology platforms such as flow chemistry, biocatalysis, and high-potency manufacturing from laboratory to commercial scale.

WuXi STA now has a process-development platform with over 1,000 scientists and five sites located in China and the US. The company’s Jinshan site currently focuses on manufacturing APIs and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the US Food and Drug Administration.

Source: STA Pharmaceutical